Search clinical trials for: Ledipasvir, sofosbuvir drug combination

Total 4887 results

Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection

Hepatitis C Virus Infection

Estonia, Russian Federation
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection

Hepatitis C Virus Infection

United States
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection

Hepatitis C Virus Infection

France, Austria, Germany, Italy
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV

Chronic Hepatitis C Virus

United States, France, Italy, United Kingdom, Germany, Spain, Puerto Rico
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis

Hepatitis C Virus Infection

United States
Egyptian Liver Hospital

Unknown

Safety & Efficacy of Sofosbuvir 400mg/Ledipasvir 90mg in the Treatment of Chronic Hepatitis C Adolescents

Hepatitis C Virus Infection, Response to Therapy of

Egypt
Right to Care
Boston University; University of California, Los Angeles; Alliance for Public... and other collaborators

Completed

Simplified Antiviral Treatment Strategy for Hepatitis C in Ukraine

Hepatitis C Virus

Ukraine
Macfarlane Burnet Institute for Medical Research...
St Vincent's Hospital Melbourne

Unknown

The TAP Study: Treating People Who Inject Drugs in Community-Based Settings Using a Social Network Approach (TAP)

Hepatitis C | Drug Abuse, Intravenous

Australia
University Health Network, Toronto

Terminated

Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)

Hepatitis C Viral Infection

Canada
Medical University of South Carolina

Completed

LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients

Hepatitis C

United States
Partners in Health

Completed

Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World (SHARED)

Chronic Hepatitis C

Rwanda
National Institutes of Health Clinical Center (CC)

Completed

Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia

HCV HIV

United States
ANRS, Emerging Infectious Diseases

Completed

Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection

HIV | Viral Hepatitis C

France
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

HCV Infection

United States, France, Australia, Puerto Rico, Spain
ANRS, Emerging Infectious Diseases

Completed

Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa (TAC)

HIV Infection | Hepatitis C

Cameroon, Côte D'Ivoire, Senegal
National Taiwan University Hospital

Completed

eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs

Hepatitis C | Viral Hepatitis C | Renal Disease

Taiwan
Massachusetts General Hospital

Terminated

Effect of Harvoni on Proteinuria and eGFR in Hepatitis C Virus Associated Chronic Kidney Disease (CKD)

Hepatitis C | Chronic Kidney Disease

United States
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection (ION-2)

Chronic Hepatitis C Virus

United States
Gilead Sciences

Completed

Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency

HCV Infection

New Zealand, United States, Puerto Rico
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection

HCV Infection

France
Ain Shams University

Unknown

Metabolic Changes in Chronic HCV Patients Receiving DAAS (HCV DAAS)

Chronic Hepatitis C

Egypt
Ottawa Hospital Research Institute
Gilead Sciences; CIHR Canadian HIV Trials Network

Completed

HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection (CTN289)

Hepatitis C, Chronic | Human Immunodeficiency Virus

Canada
University of California, San Francisco
National Institutes of Health Clinical Center (CC); Johns Hopkins University; National Institute of Allergy and Infectious Diseases (NIAID) and other collaborators

Completed

Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant (STOP-CO)

Hepatitis C | HIV | Cirrhosis

United States
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection

Hepatitis C Virus Infection

United States, New Zealand, Australia, United Kingdom
University of Texas Southwestern Medical Center
Memorial Sloan Kettering Cancer Center; Weill Medical College of Cornell University

Terminated

Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study (Optimal)

Liver Disease

United States
Wilhelminenspital Vienna
Gilead Sciences

Unknown

Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution Therapy

Chronic Hepatitis C

Austria
Gilead Sciences

Completed

Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection

Hepatitis C

Japan
National Institute of Allergy and Infectious Diseases...

Completed

Combination Therapy for Chronic Hepatitis C Infection

Hepatitis C, Chronic

United States
Genuine Research Center, Egypt
MinaPharm Pharmaceuticals

Completed

A Study of Sofosbuvir and Ledipasvir From Soviredia 90/400 mg Tablets (Minapharm, Egypt) Versus Harvoni 90/400 mg Tablets (Gilead Sciences, USA)

Healthy

Egypt
Genuine Research Center, Egypt
Magic Pharma, Egypt

Completed

A Study of Sofosbuvir and Ledipasvir From Magicbuvir Plus 90/400 mg Tablets (Magic Pharma, Egypt) Versus Harvoni 90/400 mg Tablets (Gilead Sciences, USA)

Healthy

Egypt
Gilead Sciences

Completed

Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects

Chronic Hepatitis C Virus

United States
Kaiser Permanente
City of Hope National Medical Center

Withdrawn

Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients.

Hematopoietic Stem Cell Transplantation

United States
Gilead Sciences

Completed

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment (Co-STARs)

HIV-1 Infection | HCV Infection

United States, Puerto Rico
Tanta University

Unknown

Sofosbuvir in Treatment of COVID 19

COVID

Egypt
Taipei Veterans General Hospital, Taiwan
National Taiwan University Hospital; China Medical University Hospital; Chang... and other collaborators

Withdrawn

DAA in the Risk of Recurrence After Curative Treatment of HCC

Hepatocellular Carcinoma
Stanford University
Gilead Sciences

Completed

Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6

PT-NANBH

United States
Janssen Sciences Ireland UC

Completed

A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection

Hepatitis C, Chronic

Belgium
Tanta University

Completed

Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection

Hepatitis C

Egypt
Humanity and Health Research Centre
Beijing 302 Hospital; Nanfang Hospital of Southern Medical University

Completed

DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO) (DASCO)

Chronic Hepatitis C Infection | Hepatitis B Reactivation | HBV Coinfection

China
University Hospital, Geneva
Gastaldi Giacomo; Clément Sophie

Completed

Extrahepatic Insulin Resistance in Chronic Hepatitis C

Insulin Resistance

Switzerland
Catherine Anne Chappell
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir

Hepatitis C, Chronic

United States
University of Florida
Patient-Centered Outcomes Research Institute; Merck Sharp & Dohme LLC; AbbVie

Completed

Study of Oral Treatments for Hepatitis C (PRIORITIZE)

Chronic Hepatitis C

United States
Parc de Salut Mar

Completed

Impact of Antiviral Therapy on Gastroesophageal Varices.

Cirrhosis | Chronic Hepatitis C
Radboud University Medical Center

Withdrawn

Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet (CRUSADE-1)

HCV

Netherlands, Germany
Alexandria University

Completed

HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial (RCT)

Hepatocellular Carcinoma | Hepatitis C | Neoplasm Recurrence | Treatment Complication

Egypt
National Liver Institute, Egypt

Completed

Eight Weeks Sofosbovir/Ledipasvir in HCV Infected Children Aged 4 to 10 Years

Hepatitis C, Chronic | Children, Only

Egypt
University of California, San Francisco

Completed

Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant (PRO-ACT:)

Hepatitis C | Transplantation Disease Transmission

United States
Ala'a Sharara
Gilead Sciences

Completed

Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open Label Trial

Hepatitis C | Thalassemia

Lebanon
Hospital de Clinicas de Porto Alegre
Ministry of Health, Brazil; TelessaúdeRS / UFRGS; State Secretary of Health of...

Active, not recruiting

Monitoring of Hepatitis C Treatment Using Telemedicine - a Clinical Trial in Public Health System in Brazil

Chronic Hepatitis C

Brazil
Pablo Sanchez

Completed

Expanding the Pool in Lung Transplantation

Hepatitis C | Lung Transplant

United States

3

Subscribe